Adma Biologics Stock Jumps 26% as Third-Quarter Results Show ASCENIV Growth and Raised Earnings Outlook

Adma Biologics (Nasdaq: ADMA) shares rose 26.1% on Thursday, Nov. 5, 2026, closing at $13.21 from a previous close of $10.48, while the S&P 500 ETF (SPY) fell 4.41%. Trading volume ran at about 5.2 times its usual level. The move followed the release of third-quarter results in an 8-K filed the previous evening, with the press release attached as Exhibit 99.1.

The company reported total revenue of $141.1 million for the quarter, up 5% from a year earlier. ASCENIV revenue rose 31% to $124.7 million, and GAAP net income climbed 37% to $49.9 million. Gross margin reached 71%, compared with 56% in the prior-year quarter.

Outlook raised on earnings

Adma reiterated its FY2026 revenue outlook of at least $530 million. It increased its minimum expectations for Adjusted Net Income to at least $180 million and for Adjusted EBITDA to at least $275 million. Management said favorable ASCENIV utilization trends had continued into the fourth quarter.

BIVIGAM revenue declined

BIVIGAM revenue fell to $15.4 million from $19.4 million in the second quarter. The company attributed the decline to competitive pricing and channel inventory pressures in the standard immunoglobulin market, and said underlying end-user utilization showed encouraging signs of stabilization.

SG-001 regulatory feedback

Adma said it received constructive FDA feedback on the pre-IND meeting package for SG-001, its investigational pneumococcal hyperimmune globulin candidate, and intends to advance preparations for an IND submission.

Cantor Fitzgerald raised its price target on the stock to $13 from $12 and kept a Neutral rating.

The company also reported share repurchases of 2.7 million shares in the third quarter and said it remains on track for its previously stated target of $200 million or more in 2026 buybacks.